029 Group SE

Earnings Release • Apr 6, 2004

News Details

Ad-hoc | 6 April 2004 10:24

Rhein Biotech N.V. reports 2003 Full Year results

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Maastricht, April 6, 2004 Rhein Biotech N.V. reports for the Full Year 2003 net sales of 33.8 million Euro. The EBITDA was 0.2 million Euro, while the loss from operations (EBIT) was -12.0 million Euro. Rhein Biotech’s net loss in 2003 was -12.9 million Euro. The company’s cash position at the end of December 2003 was 22.8 million Euro. Consolidated income statement for the year ending December 31, 2003 The results are unaudited Dutch GAAP; in ‘000 EUR 2003 Net sales 33’754 Loss from Operations (EBIT) -11’999 Fianancial result, net -2’879 Other operating income 373 Loss before taxes -14’505 Taxes 104 Minority interest 1’527 Consolidated net loss -12’874 EBITDA 163 end of ad-hoc-announcement (c)DGAP 06.04.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Rhein Biotech is now a member of the Berna Biotech Group, a leading player for innovation in vaccines. For further information Rhein Biotech N.V. Company Contact: Béatrice Keller Communication Manager E: communications@bernabiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 061024 Apr 04